Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

被引：0
|
作者：
Amy D Guertin
Melissa M Martin
Brian Roberts
Melissa Hurd
Xianlu Qu
Nathan R Miselis
Yaping Liu
Jing Li
Igor Feldman
Yair Benita
Andrew Bloecher
Carlo Toniatti
Stuart D Shumway
机构：
[1] Merck Research Laboratories,Department of Oncology
[2] Amgen,Department of In Vivo Pharmacology
[3] Hudson Alpha Institute,Molecular Biomarkers
[4] Merck Research Laboratories,Screening and Protein Sciences
[5] Merck Research Laboratories,Informatics and Analysis
[6] Merck Research Laboratories,undefined
[7] Merck Research Laboratories,undefined
[8] Institute for Applied Cancer Science,undefined
来源：
Cancer Cell International | / 12卷
关键词：
LoVo Cell; Sensitive Cell Line; Checkpoint Kinase; CHK1 Inhibitor; CHK1 Kinase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Overcoming MK1775 resistance in upper gastrointestinal cancers with combined WEE1 and CHK1 inhibition
    Thangaretnam, Krishnapriya
    Islam, Md Obaidul
    Lu, Heng
    Peng, Dunfa
    Bhat, Nadeem Sidiq
    Soutto, Mohammed
    Wael, EL-Rifai
    Chen, Zheng
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer
    Chao, Yapeng
    Chen, Yuzhou
    Zheng, Wenxiao
    Demanelis, Kathryn
    Liu, Yu
    Connelly, Jaclyn A.
    Wang, Hong
    Li, Song
    Wang, Qiming Jane
    ONCOGENE, 2024, 43 (11) : 789 - 803
  • [23] Positive regulation of Wee1 by Chk1 and 14-3-3 proteins
    Lee, J
    Kumagai, A
    Dunphy, WG
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (03) : 551 - 563
  • [24] WEE1 and CHK1 gene silencing using Polypurine Reverse Hoogsteen Hairpins
    Aubets, E.
    Ciudad, C. J.
    Noe, V.
    HUMAN GENE THERAPY, 2019, 30 (11) : A64 - A64
  • [25] Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
    Fanying Meng
    Deepthi Bhupathi
    Jessica D Sun
    Qian Liu
    Dharmendra Ahluwalia
    Yan Wang
    Mark D Matteucci
    Charles P Hart
    BMC Cancer, 15
  • [26] ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
    Ronco, Cyril
    Martin, Anthony R.
    Demange, Luc
    Benhida, Rachid
    MEDCHEMCOMM, 2017, 8 (02) : 295 - 319
  • [27] Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
    Meng, Fanying
    Bhupathi, Deepthi
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Wang, Yan
    Matteucci, Mark D.
    Hart, Charles P.
    BMC CANCER, 2015, 15
  • [28] Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation
    Restelli, Valentina
    Vagni, Micaela
    Arribas, Alberto J.
    Bertoni, Francesco
    Damia, Giovanna
    Carrassa, Laura
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 129 - 133
  • [29] CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
    Chaudhuri, Leena
    Vincelette, Nicole D.
    Koh, Brian D.
    Naylor, Ryan M.
    Flatten, Karen S.
    Peterson, Kevin L.
    McNally, Amanda
    Gojo, Ivana
    Karp, Judith E.
    Mesa, Ruben A.
    Sproat, Lisa O.
    Bogenberger, James M.
    Kaufmann, Scott H.
    Tibes, Raoul
    HAEMATOLOGICA, 2014, 99 (04) : 688 - 696
  • [30] Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
    Hauge, Sissel
    Naucke, Christian
    Hasvold, Grete
    Joel, Mrinal
    Rodland, Gro Elise
    Juzenas, Petras
    Stokke, Trond
    Syljuasen, Randi G.
    ONCOTARGET, 2017, 8 (07) : 10966 - 10979
12345